Cypress Bioscience, Inc.

Other

Sova Pharmaceuticals, Inc.

Collegium Pharmaceutical, Inc.

Atai Therapeutics Inc.

Qualcomm Incorporated

Atai Life Sciences Ag

Royalty Pharma Collection Trust

Srinivas G Rao

Jay D Kranzler

Glenn Short

Sergio G Durón

Thang Huy Vu

Justin Chapman

Gregory Stein

Simon G Sydserff

Robert B Perni

Roman V Rariy

Jane C Hirsh

Tanweer A Khan

Sergio G Duron

Michael Heffernan

Steve Roth

Shubha Chungi

Warren Stanfield Wade

Clifton Eugene Scott

Majed Fawaz

Jai Krishnamurthy

Laxmi Rayapudi

Michael Gendreau

Richard L Prenoveau

Glen Short

Santnu Patel

Prerak Patel

Clifton E Scott

Pharmaceutical compositions including an amorphous N—N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.

N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

Prodrugs and conjugates of dimethyltryptamine

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. 

A composition including N,N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof capable of exhibiting a therapeutically effective blood level of DMT from between about 20 and about 60 minutes when administered to a human. A method of treating a neurological disease or condition comprising administering buccally, sublingually, subcutaneously or intranasally to a subject in need thereof an effective amount of DMT or a pharmaceutically acceptable salt thereof, capable of exhibiting a therapeutically effective level of DMT from for between about 20 to about 60 minutes when administered to a human.

N,N-dimethyltryptamine compositions and methods

The present invention relates generally to systems for measuring pH. In particular, the present invention relates to a continuous flow system having one or more solid state pH sensors positioned within a fluid pathway of the system to provide continuous pH measurement.

Solid state pH sensing continuous flow system

Solid-state electrodes comprising Redox Active Surface Areas for use in analyte sensing devices and various product platform devices.

Solid state electrodes and sensors having redox active surface areas

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-&#x3b3;-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Cystathionine-gamma-lyase (CSE) inhibitors

Cystathionine-&#x3b3;-lyase (CSE) inhibitors

A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a Tof 4-10 hours.

Modified release compositions of milnacipran

The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.

Milnacipran for the long-term treatment of fibromyalgia syndrome

The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain

Growing community of inventors

Encinitas, CA, United States of America

Srinivas G Rao